Fidelity Investments
CYCN

Fidelity Investments’s Cyclerion Therapeutics CYCN Stock Holding History

Fidelity Investments’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2M Buy
649,547
+644,807
+13,604% +$2.09M ﹤0.01% 2722
2026
Q1 		$7.28K Hold
4,740
– – ﹤0.01% 4844
2025
Q4 		$6.02K Sell
4,740
-6
-0.1% -$11 ﹤0.01% 4854
2025
Q3 		$10.9K Buy
4,746
+6
+0.1% +$16 ﹤0.01% 4582
2025
Q2 		$13.8K Sell
4,740
-200
-4% -$597 ﹤0.01% 4425
2025
Q1 		$12.2K Buy
4,940
+200
+4% +$595 ﹤0.01% 4434
2024
Q4 		$15.3K Sell
4,740
-152,896
-97% -$426K ﹤0.01% 4295
2024
Q3 		$407K Sell
157,636
-3,783
-2% -$11.1K ﹤0.01% 2937
2024
Q2 		$368K Sell
161,419
-908
-0.6% -$2.58K ﹤0.01% 2837
2024
Q1 		$519K Sell
162,327
-522
-0.3% -$1.67K ﹤0.01% 2706
2023
Q4 		$546K Sell
162,849
-1,700
-1% -$4.91K ﹤0.01% 2661
2023
Q3 		$559K Sell
164,549
-400
-0.2% -$1.44K ﹤0.01% 2601
2023
Q2 		$678K Sell
164,949
-4,569
-3% -$23.7K ﹤0.01% 2569
2023
Q1 		$1.47M Sell
169,518
-1,530
-0.9% -$19.3K ﹤0.01% 2441
2022
Q4 		$2.24M Buy
171,048
+355
+0.2% +$4.2K ﹤0.01% 2345
2022
Q3 		$2.94M Buy
170,693
+43,807
+35% +$753K ﹤0.01% 2321
2022
Q2 		$1.39M Sell
126,886
-3,865
-3% -$55.4K ﹤0.01% 2594
2022
Q1 		$2.9M Sell
130,751
-120
-0.1% -$2.89K ﹤0.01% 2503
2021
Q4 		$4.5M Sell
130,871
-1,560
-1% -$73.7K ﹤0.01% 2395
2021
Q3 		$8.13M Sell
132,431
-1,310
-1% -$85.7K ﹤0.01% 2196
2021
Q2 		$10.4M Sell
133,741
-2,575
-2% -$161K ﹤0.01% 2089
2021
Q1 		$7.61M Buy
136,316
+330
+0.2% +$24.8K ﹤0.01% 2139
2020
Q4 		$8.32M Sell
135,986
-850
-0.6% -$57.9K ﹤0.01% 2027
2020
Q3 		$16.6M Sell
136,836
-370
-0.3% -$42.3K ﹤0.01% 1638
2020
Q2 		$16.2M Sell
137,206
-1
-0% -$84 ﹤0.01% 1632
2020
Q1 		$7.27M Buy
137,207
+10,633
+8% +$759K ﹤0.01% 1801
2019
Q4 		$6.88M Sell
126,574
-10,265
-8% -$959K ﹤0.01% 1971
2019
Q3 		$33.2M Sell
136,839
-23
-0% -$4.97K ﹤0.01% 1363
2019
Q2 		$31.3M Buy
+136,862
New +$38.7M ﹤0.01% 1428

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments's CYCN Position: Q2 2026 in Review

Fidelity Investments increased its Cyclerion Therapeutics (CYCN) stake by 13,604% in Q2 2026, buying an estimated $2.09M and bringing the position to 649,547 shares worth $2.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2722.

Fidelity Investments first reported a position in CYCN in Q2 2019 and has held it in 29 quarters since. The position peaked at $33.2M in Q3 2019. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Fidelity Investments held 649,547 shares of Cyclerion Therapeutics worth $2.2M as of Q2 2026.
  • Fidelity Investments bought 644,807 Cyclerion Therapeutics shares in Q2 2026, an estimated $2.09M.
  • Cyclerion Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2722 holding.
  • Fidelity Investments first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Fidelity Investments's Cyclerion Therapeutics position peaked at $33.2M in Q3 2019.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.